ClinicalTrials.gg
CompletedNCT04388319BuZonEUpdated Apr 13, 2022Results posted

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

A Phase 3 interventional study of Zonisamide and Bupropion in Smoking Cessation, sponsored by Rose Research Center, LLC. Completed at 2 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-13.

Sponsored by Rose Research Center, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing bupropion in Smoking Cessation — 4 open to participants now, 4 under way, 2 of them phase 3. Bupropion · Smoking Cessation.

Enrollment
40th of 48
26 · median 162
Started
2020
with 1 other
Phase 3
14 of 48
2 open now
Registered
39th of 48
by date
Lead sponsor
2 of 48
Rose Research Center, LLC

Among the 48 studies testing bupropion in Smoking Cessation, this one is the 40th largest by enrollment, is one of 2 that started in 2020, is one of 14 in phase 3, and was the 39th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

4 of the 48 studies testing bupropion in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bupropion

Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing bupropion in Smoking Cessation, or all of them as a file.
02

Study summary

This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline data on use of combustible cigarettes. Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide (100 mg/daily) and will begin extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) in addition to continued use of the G6. At each visit, participants will receive enough zonisamide, bupropion, and Halo G6 cartomizers to last until their next study visit. Halo G6 and combination zonisamide and bupropion use will continue until the participant returns for the End-of-Study visit (V7).

03

Conditions studied

  • Smoking Cessation

Keywords

  • e-cigarette
  • zonisamide
  • bupropion
  • combustible cigarettes
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has signed the ICF and is able to read and understand the information provided in the ICF.
  2. Is 21 to 65 years of age (inclusive) at screening.
  3. Smokes at least 10 commercially available cigarettes per day (no brand restrictions), for the last 12 months.
  4. Has an expired air CO reading of at least 10 ppm at screening.
  5. Interested in switching to an electronic cigarette.
  6. Willing and able to comply with the requirements of the study.
  7. Owns a smart phone with text message and data capabilities compatible with necessary surveys.

Exclusion criteria

Exclusion Criteria:

  1. Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, , concomitant medications and medical history).
  2. PHQ-9 score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening.
  3. Planned use of an FDA-approved smoking cessation product during the study.
  4. High blood pressure (systolic > 150 mmHg or diastolic >95 mmHg) at screening.
  5. (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2.
  6. Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.
  7. Has received psychotherapy or behavioral treatments potentially impacting symptoms of depression, anxiety, or nicotine withdrawal within 30 days of screening, or during the study.
  8. Taking antidepressants, psychoactive medications (e.g. antipsychotics, benzodiazepines, hypnotics) or medications that prolong .
  9. Use of any of these products in the past 30 days:

    1. Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, methamphetamines, or opiates);
    2. Experimental () drugs that are unknown to participant;
    3. Chronic opiate use.
  10. Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black \& Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.
  11. Pregnant or nursing (by self-report) or has a positive pregnancy test.
  12. Enrollment requirements met.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Combination zonisamide and bupropion with e-cigarette

    Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.

    Drug: Zonisamide · Drug: Bupropion · Other: Halo G6 e-cigarette

Interventions

  • Zonisamide (100 mg/daily) for 12 weeks.

    Also known as: zonegran

  • Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.

    Also known as: wellbutrin, Zyban

  • OtherHalo G6 e-cigarette

    G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.

    Also known as: e-cigarette

06

What researchers measure

Primary outcomes

  1. Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes

    Defined as self-report of no cigarette smoking (not even a puff), confirmed by an expired air CO reading of less than 5 ppm.

    Time frame: Weeks 8-11 post-quit date (weeks 10-13 post baseline)

Secondary outcomes

  1. Point Abstinence From Combustible Cigarettes

    Assessed by self-report utilizing an automated SMS messaging system.

    Time frame: Six months post switch day (approximately 6 months post baseline)

  2. Change in Rewarding Effects of Smoking Combustible Cigarettes

    Characterize changes in the two primary scales of the Cigarette Evaluation Questionnaire (mCEQ), assessing smoking satisfaction and psychological reward, compared between cigarettes smoked after meals versus all others smoked during the day, examining how this difference changes after zonisamide/bupropion usage. The mCEQ uses a 7-point scale (0=Not at all; 1=Very little; 2=A little; 3=Moderately; 4=A lot, 5=Quite a lot; 6=Extremely) to measure the following subscales: Satisfaction, Psychological Reward, Enjoyment of Respiratory Tract Sensations, Craving Reduction, Aversion.

    Time frame: First week compared to after start of study drugs (Weeks 2-13 post baseline)

07

Results

Posted Mar 29, 2022

Participant flow

Enrolled in Study
Participant flow — Enrolled in Study
MilestoneCombination Zonisamide and Bupropion With E-cigarette
Started26
Completed24
Not completed2
Treatment Period
Participant flow — Treatment Period
MilestoneCombination Zonisamide and Bupropion With E-cigarette
Started24
Completed23
Not completed1

Outcome measures

PrimaryNumber of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes

Defined as self-report of no cigarette smoking (not even a puff), confirmed by an expired air CO reading of less than 5 ppm.

Time frame:
Weeks 8-11 post-quit date (weeks 10-13 post baseline)
Reported as:
Count of participants · Participants
Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes
ParticipantsCombination Zonisamide and Bupropion With E-cigarette
Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes8
SecondaryPoint Abstinence From Combustible Cigarettes

Assessed by self-report utilizing an automated SMS messaging system.

Time frame:
Six months post switch day (approximately 6 months post baseline)
Reported as:
Count of participants · Participants
Point Abstinence From Combustible Cigarettes
ParticipantsCombination Zonisamide and Bupropion With E-cigarette
Point Abstinence From Combustible Cigarettes15
SecondaryChange in Rewarding Effects of Smoking Combustible Cigarettes

Characterize changes in the two primary scales of the Cigarette Evaluation Questionnaire (mCEQ), assessing smoking satisfaction and psychological reward, compared between cigarettes smoked after meals versus all others smoked during the day, examining how this difference changes after zonisamide/bupropion usage. The mCEQ uses a 7-point scale (0=Not at all; 1=Very little; 2=A little; 3=Moderately; 4=A lot, 5=Quite a lot; 6=Extremely) to measure the following subscales: Satisfaction, Psychological Reward, Enjoyment of Respiratory Tract Sensations, Craving Reduction, Aversion.

Time frame:
First week compared to after start of study drugs (Weeks 2-13 post baseline)
Reported as:
Mean · score on a scale
Change in Rewarding Effects of Smoking Combustible Cigarettes
score on a scaleCombination Zonisamide and Bupropion With E-cigarette
CEQ Satisfaction Scale0 ± 1.2
CEQ Psych Reward Scale0.2 ± 1.1

Adverse events

Collected over During 13 week study period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Zonisamide and Bupropion With E-cigarette0/24 (0%)0/24 (0%)22/24 (91.7%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCombination Zonisamide and Bupropion With E-cigarette
ConstipationGastrointestinal disorders5/24
HeadacheNervous system disorders5/24
Throat irritationGastrointestinal disorders4/24
NauseaGastrointestinal disorders4/24
CoughRespiratory, thoracic and mediastinal disorders2/24
TinnitusNervous system disorders2/24
Dry mouthGastrointestinal disorders2/24
DizzinessNervous system disorders2/24
Aversion to cigarettesNervous system disorders2/24
AnxietyNervous system disorders2/24

Baseline characteristics

Two participants were enrolled into the study but discontinued prior to taken any study drug so analysis is based on the 24 participants who started the study drug.

Age, Categorical
Age, Categorical(Participants)Combination Zonisamide and Bupropion With E-cigarette
<=18 years0
Between 18 and 65 years26
>=65 years0
Age, Continuous
Age, Continuous(years)Combination Zonisamide and Bupropion With E-cigarette
Mean45.1 ± 9.75
Sex: Female, Male
Sex: Female, Male(Participants)Combination Zonisamide and Bupropion With E-cigarette
Female8
Male18
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Combination Zonisamide and Bupropion With E-cigarette
Hispanic or Latino1
Not Hispanic or Latino25
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Combination Zonisamide and Bupropion With E-cigarette
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American6
White18
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Combination Zonisamide and Bupropion With E-cigarette
United States26
Cigarettes smoked per day (CPD)
Cigarettes smoked per day (CPD)(Cigs smoked per day)Combination Zonisamide and Bupropion With E-cigarette
Mean21.2 ± 6.64
FTND -- The Fagerström Test for Nicotine Dependence Score
FTND -- The Fagerström Test for Nicotine Dependence Score(units on a scale)Combination Zonisamide and Bupropion With E-cigarette
Mean6.1 ± 1.82

1 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Rose Research Center
    Charlotte, North Carolina 28262, United States
  • Rose Research Center
    Raleigh, North Carolina 27617, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jun 2021, 12 months.

Results were first posted in Mar 2022, 9 months after primary completion.

Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2020
First posted
May 14, 2020
StartActual
May 27, 2020
Primary completionActual
Jun 4, 2021
CompletionActual
Sep 15, 2021
Results first posted
Mar 29, 2022
Last update
Apr 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04388319
Lead sponsor
Rose Research Center, LLC
Collaborators
Foundation for a Smoke Free World INC
Responsible party
Sponsor
First posted
May 14, 2020
Start date
May 27, 2020
Primary completion
Jun 4, 2021
Completion
Sep 15, 2021
Results posted
Mar 29, 2022
Last update
Apr 13, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zonisamide · Bupropion

Start the discussion